GWAS-identified genetic variants associated with medication-assisted treatment outcomes in patients with opioid use diso
- PDF / 329,514 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 104 Downloads / 185 Views
PROTOCOL
Open Access
GWAS-identified genetic variants associated with medication-assisted treatment outcomes in patients with opioid use disorder: a systematic review and metaanalysis protocol Caroul Chawar1,2, Alannah Hillmer1,2, Stephanie Sanger3, Alessia D’Elia1,2, Balpreet Panesar1,2, Lucy Guan2,4, Dave Xiaofei Xie2,4, Nandini Bansal2,4, Aamna Abdullah2,4, Flavio Kapczinski2, Guillaume Pare5,6, Lehana Thabane5,6,7 and Zainab Samaan2*
Abstract Background: The burden of opioid use disorder (OUD) has been increasing in North America. Administration of medication-assisted treatments (MATs) for OUD on an individual-dose basis has been shown to affect patient responses to treatment, proving to be, on occasion, dangerous. A genetic basis has been identified for some MAT responses in a candidate gene context, but consensus has not been reached for any genome-wide significant associations. This systematic review aims to identify and assess any genetic variants associated with MAT patient outcomes at genome-wide significance. Methods: The databases searched by the authors will be: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINA HL, GWAS Catalog, GWAS Central, and NIH Database of Genotypes and Phenotypes. A title and abstract screening, full-text screening, data extraction, and quality assessment will be completed in duplicate for each study via Covidence. Treatment outcomes of interest include continued opioid use or abstinence during treatment or at follow-up, time to relapse, treatment retention rates, opioid overdose, other substance use, comorbid psychiatric disorders, risk taking behaviors, MAT plasma concentrations, and mortality rates. Analysis methods applied, if appropriate, will include random effects meta-analysis with pooled odds ratios for all outcomes. Subgroup analyses will also be implemented, when possible. Discussion: This systematic review can hopefully inform the direction of future research, aiding in the development of a safer and more patient-centered treatment. It will be able to highlight genome-wide significant variants that are replicable and associated with MAT patient outcomes. (Continued on next page)
* Correspondence: [email protected] 2 Department of Psychiatry and Behavioural Neurosciences, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutor
Data Loading...
